natgillin/translations-raw huggingface dataset:
The co-primary endpoints were percentage change from baseline in pulmonary vascular resistance (PVR) and change from baseline in 6-minute walk distance to Month 6 versus placebo. 
Dodatni primarni opazovani dogodki so bile spremembe od izhodiščne vrednosti pri pljučno-žilnem uporu (PŽU) in sprememba prehojene razdalje v 6 minutah hoje od izhodiščne vrednosti do 6. meseca proti placebu.
Tell your doctor immediately if you are breast-feeding. 
Svojemu zdravniku takoj povejte, če dojite.
Elevations to ≥ 8 × ULN were seen in 3.6% of the bosentan-treated patients and 0.4% of the placebo-treated patients. 
Zvišanja do ≥ 8 × ZMN so opazili pri 3,6 % bolnikov, ki so jemali bosentan, in 0,4 % bolnikov, ki so prejemali placebo.
In adult patients, the exposure to the active metabolite is greater than in healthy subjects. 
Odrasli bolniki so bolj izpostavljeni aktivnemu presnovku kot zdrave osebe.
Treatment with bosentan resulted in fewer new digital ulcers for the duration of therapy, compared with placebo. 
Zdravljenje z bosentanom je v primerjavi s placebom pripeljalo do manj novih razjed prstov med trajanjem terapije.
In a retrospective responder analysis based on change in walking distance, WHO functional class and dyspnoea of the 95 patients randomised to bosentan 125 mg twice daily in the placebo-controlled studies, it was found that at week 8, 66 patients had improved, 22 were stable and 7 had deteriorated. 
Za bolnike, ki so se odzvali na zdravljenje, je kasnejša retrospektivna analiza na podlagi spremembe prehojene razdalje, funkcijskega razreda po klasifikaciji SZO in dispneje pri 95 bolnikih, ki so v randomiziranih s placebom nadzorovanih preskušanjih jemali bosentan v odmerku 125 mg dvakrat na dan, pokazala, da je po 8 tednih pri 66 bolnikih prišlo do izboljšanja stanja, pri 22 bolnikih je bilo stanje stabilno, pri 7 bolnikih pa je prišlo do poslabšanja.
In the adult placebo-controlled studies, a decrease in haemoglobin concentration to below 10 g/dL from baseline was reported in 8.0% of bosentan-treated patients and 3.9% of placebo-treated patients (see section 4.4). 
V s placebom nadzorovani študiji pri odraslih so poročali o znižanju koncentracije hemoglobina na manj kot 10 g/dl od izhodiščne vrednosti za 8,0 % bolnikov, ki so jemali bosentan, in 3,9 % bolnikov, ki so prejemali placebo (glejte poglavje 4.4).
No dose adjustment of STAYVEER is considered necessary. 
Prilagoditev odmerka zdravila STAYVEER ni potrebna.
Based on the findings in studies BREATHE-3, FUTURE 1, and FUTURE-3, it appears that the exposure to bosentan reaches a plateau at lower doses in paediatric patients than in adults, and that doses higher than 2 mg/kg twice daily (4 mg/kg twice daily or 2 mg/kg three times daily) will not result in greater exposure to bosentan in paediatric patients. 
Na podlagi izsledkov študij BREATHE-3, FUTURE 1 in FUTURE-3 kaže, da doseže izpostavljenost bosentanu vrhunec pri pediatričnih bolnikih z nižjimi odmerki kot pri odraslih in da odmerki, višji od 2 mg/kg dvakrat na dan (4 mg/kg dvakrat dnevno ali 2 mg/kg trikrat dnevno) pri pediatričnih bolnikih ne bodo povzročili večje izpostavljenosti bosentanu.
• Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease 
• pljučni arterijski hipertenziji, ki je posledica skleroderme brez resne intersticijske pljučne bolezni,
The most frequent adverse reactions are headache (11.5%), oedema / fluid retention (13.2%), abnormal liver function test (10.9%) and anaemia / haemoglobin decrease (9.9%). 
(11,5 %), edem/zastajanje vode (13,2 %), nenormalne vrednosti preiskav delovanja jeter (10,9 %) in anemija/zmanjšanje ravni hemoglobina (9,9 %).
STAYVEER is not recommended in paediatric patients with systemic sclerosis and ongoing digital ulcer disease. 
Uporaba zdravila STAYVEER se ne priporoča pri pediatričnih bolnikih s sistemsko sklerozo in napredujočo boleznijo razjed prstov.
However, STAYVEER can induce hypotension (decrease of your blood pressure) which can make you feel dizzy, affect your vision and affect your ability to drive and use machines. 
Zdravilo STAYVEER lahko povzroči hipotenzijo (znižanje krvnega tlaka), zaradi česar ste lahko omotični, ali poslabšanje vida, kar lahko vpliva na vašo sposobnost vožnje ali uporabe strojev.
Slightly increased incidence of testicular tubular atrophy was observed in rats given bosentan orally at doses as low as 125 mg/kg/day (about 4 times the maximum recommended human dose [MRHD] and the lowest doses tested) for two years but not at doses as high as 1,500 mg/kg/day (about 50 times the MRHD) for 6 months. 
Rahlo povečano pojavnost tubularne atrofije testisov so opazili pri podganah, ki so jim dve leti dajali bosentan peroralno v odmerkih, ki niso presegali 125 mg/kg/dan (približno 4-kratni najvišji priporočeni odmerek pri ljudeh [MRHD] in najnižji preskušani odmerek), ne pa tudi pri tako visokih odmerkih kot je 1500 mg/kg/dan (približno 50-krat MRHD), ki so jih dajali 6 mesecev.
The ‘class' reflects the seriousness of the disease: ‘class III' involves marked limitation of physical activity. 
‘Razred' odraža resnost bolezni: ‘III.
Take this card to your doctor or your gynaecologist at your next visit and he/she will be able to advise you on whether you need to use additional or alternative contraceptive methods. 
Ob naslednjem obisku zdravnika ali ginekologa vzemite to kartico s seboj, da vam bo lahko svetoval/a glede potrebe po dodatni ali drugi kontracepcijski metodi.
In the post-marketing period rare cases of liver cirrhosis and liver failure have been reported. 
V obdobju trženja so poročali o redkih primerih jetrne ciroze in jetrne odpovedi.
STAYVEER contains sodium 
STAYVEER vsebuje natrij
When administered concomitantly with lopinavir+ritonavir, or other ritonavir-boosted protease inhibitors, the patient's tolerability of STAYVEER should be monitored. 
Pri sočasnem dajanju lopinavirja in ritonavirja ali drugih zaviralcev proteaze, ki jih okrepi ritonavir, je treba nadzirati prenašanje zdravila STAYVEER pri bolniku.
2 Hypersensitivity reactions were reported in 9.9% of patients on bosentan and 9.1% of patients on placebo. 
2 O preobčutljivostni reakciji so poročali pri 9,9 % bolnikov na bosentanu in 9,1 % bolnikov na placebu.
After a single intravenous dose of 250 mg, the clearance was 8.2 L/h. 
Biotransformacija in izločanje Po enkratnem intravenskem odmerku 250 mg je bil očistek 8,2 l/h.
Pharmacokinetic data are not available for STAYVEER in young children with this disease. 
STAYVEER pri majhnih otrocih s to boleznijo niso na voljo.
For white high-density polyethylene bottles, use within 30 days after the first opening. 
Vsebino belih plastenk iz polietilena visoke gostote porabite v 30 dneh po prvem odprtju.
Treatment with diuretics should be considered in patients with evidence of fluid retention before the start of treatment with STAYVEER. 
O zdravljenju z diuretiki razmislimo pri bolnikih z znaki zadrževanja tekočine že pred začetkom zdravljenja z zdravilom STAYVEER.
Digoxin: Co-administration for 7 days of bosentan 500 mg twice daily with digoxin decreased the AUC, Cmax and Cmin of digoxin by 12%, 9% and 23%, respectively. 
Digoksin: Pri 7-dnevni sočasni uporabi bosentana v odmerku 500 mg dvakrat na dan z digoksinom so se znižale vrednosti AUCτ, Cmax in Cmin digoksina za 12 %, 9 % oziroma 23 %.
Of the 7 patients who deteriorated at week 8, 3 improved at week 12/16 and 4 deteriorated compared with baseline. 
Od 7 bolnikov s poslabšanjem stanja v 8. tednu se je pri 3 bolnikih stanje izboljšalo v 12./16.
An open-label, non-comparative study (AC-052-362 [BREATHE-4]) was performed in 16 patients with WHO functional class III PAH associated with HIV infection. 
V odprti, neprimerjalni študiji (AC-052-362 [BREATHE-4]) je sodelovalo šestnajst bolnikov s PAH III. razreda po klasifikaciji SZO, povezanim z okužbo HIV.
If the aminotransferase levels return to pre-treatment values continuing or re-introducing STAYVEER according to the conditions described below should be considered. 
Če se ravni aminotransferaz vrnejo na vrednosti pred zdravljenjem, je treba presoditi o nadaljevanju ali ponovni uvedbi zdravljenja z zdravilom STAYVEER v skladu s spodaj opisanimi pogoji.
Neutropenia, leukopenia1 
občasni nevtropenija, levkopenija1
Name and address of the manufacturer responsible for batch release 
PROIZVAJALEC, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov proizvajalca, odgovornega za sproščanje serij
Concomitant administration of both a CYP3A4 inhibitor and a CYP2C9 inhibitor with STAYVEER should be avoided (see section 4.5). 
Izogibati se moramo sočasni uporabi zaviralcev CYP3A4 in CYP2C9 z zdravilom STAYVEER (glejte poglavje 4.5).
In the overall population (n = 31), 2 mg/kg twice daily resulted in a daily exposure of 8,535 ng·h/mL; AUCτ was 4,268 ng·h/mL (CV: 61%). 
Pri celotni populaciji (n = 31) z odmerkom 2 mg/kg dvakrat dnevno je bila dnevna izpostavljenost 8.535 ng·h/ml, AUCτ pa 4.268 ng·h/ml (CV: 61 %).
In study AC-052-365 (FUTURE 1), dispersible tablets were administered in 36 PAH children aged from 2 to 11 years. 
V študiji AC-052-365 (FUTURE 1) je 36 otrok s PAH, starih 2-11 let prejemalo disperzibilne tablete.
An interaction study between bosentan and lopinavir+ritonavir in healthy subjects showed increased plasma concentrations of bosentan, with the maximum level during the first 4 days of treatment (see section 4.5). 
Študija medsebojnega delovanja med bosentanom in lopinavirjem in ritonavirjem pri zdravih prostovoljcih je pokazala zvišane koncentracije bosentana v plazmi z največjo ravnijo v prvih 4 dneh zdravljenja
Consequently, should signs of pulmonary oedema occur when STAYVEER is administered in patients with PAH, the possibility of associated venoocclusive disease should be considered. 
Zato moramo v primeru, da se pri bolnikih s PAH, ko prejemajo zdravilo STAYVEER, pojavijo znaki pljučnega edema, pomisliti na možnost sočasne venookluzivne bolezni.
The Kaplan-Meier event-free estimate for worsening of PAH (death, lung transplantation, or hospitalisation for PAH worsening) at 24 weeks was 96.9% and 96.7% in the twice daily and three times daily groups, respectively. 
Po Kaplan-Meierjevem izračunu je bilo po 24 tednih brez dogodkov poslabšanja PAH (smrt, presaditev pljuč ali hospitalizacija zaradi poslabšanja PAH) 96,9 % bolnikov izmed tistih, ki so prejemali zdravilo dvakrat dnevno, in 96,7 % tistih, ki so prejemali zdravilo trikrat dnevno.
AC-052-355 was a multi-centre, randomised, double-blind, parallel-group study of bosentan versus placebo in 33 patients with severe PAH who were receiving concomitant epoprostenol therapy. 
AC-052-355 je bila randomizirana multicentrična dvojno slepa študija, v kateri so s pomočjo vzporedne skupine primerjali bosentan s placebom pri 33 bolnikih s hudo PAH, ki so sočasno prejemali epoprostenol.
A volume of distribution (Vss) of about 18 litres was determined after an intravenous dose of 250 mg. 
Po intravenskem odmerku 250 mg je bil ugotovljeni volumen porazdelitve (Vss) približno 18 litrov.
• Headache • Oedema (swelling of the legs and ankles or other signs of fluid retention) 
• edem (otekanje nog in gležnjev in drugi znaki zastajanja tekočine)
Because STAYVEER may make hormonal contraception (e.g., oral, injection, implant, or skin patches) ineffective, this method on its own is not reliable. 
Ker lahko zdravilo STAYVEER povzroči neučinkovitost hormonske kontracepcije (npr. peroralne oblike, oblike za injiciranje, vsadki ali kožni obliži), ta način sam ni zanesljiv.
If it is possible that you could become pregnant, use a reliable form of birth control (contraception) while you are taking STAYVEER. 
Če je možno, da zanosite, uporabite zanesljivo obliko kontracepcije, medtem ko jemljete zdravilo
At steady state, bosentan plasma concentrations were 3- to 4-fold higher than with bosentan alone. 
V stanju dinamičnega ravnovesja so bile plazemske koncentracije bosentana 3- do 4-krat višje kot pri jemanju bosentana samega.
The combination of bosentan and epoprostenol has been investigated in two studies: AC-052-355 (BREATHE-2) and AC-052-356 (BREATHE-3). 
Kombinacija z epoprostenolom Kombinacijo bosentana in epoprostenola so raziskovali v dveh študijah: AC-052-355 (BREATHE-2)
This study was primarily designed as a pharmacokinetic study (see section 5.2). 
Ta študija je bila zasnovana predvsem kot farmakokinetična študija (glejte poglavje 5.2).
In the 20 integrated placebo-controlled studies, elevations in liver aminotransferases ≥ 3 ×ULN were observed in 11.2% of the bosentan-treated patients as compared to 2.4% of the placebo-treated patients. 
V 20 integriranih s placebom nadzorovanih študijah so opazili povišanja vrednosti jetrnih aminotransferaz za ≥ 3 × vrednost ZMN, in to pri 11,2 % bolnikov, ki so jemali bosentan, in 2,4 % bolnikov, ki so prejemali placebo.
On day 9, plasma concentrations of bosentan were approximately 5-fold higher than with bosentan administered alone. 
9. dan so bile koncentracije bosentana v plazmi približno 5-krat višje kot pri dajanju samega bosentana.
Therefore, women of childbearing potential must not use hormonal contraceptives (including oral, injectable, transdermal or implantable forms) as the sole method of contraception but must use an additional or an alternative reliable method of contraception. 
(vključno s peroralnimi, transdermalnimi oblikami, oblikami za vbrizganje ali vsadki) kot edinega načina kontracepcije, temveč morajo uporabljati dodatno ali drugo zanesljivo metodo kontracepcije.
He had symptoms of nausea, vomiting, hypotension, dizziness, sweating and blurred vision. 
hipotenzije, omotičnosti, potenja in zamegljenega vida.
Consequently, bosentan is not expected to increase the plasma concentrations of medicinal products metabolised by these isoenzymes. 
Zato ne pričakujemo, da bi bosentan povišal plazemske koncentracije zdravil, ki jih presnavljajo ti izoencimi.
Anaphylaxis and/or angioedema1 
redki anafilaksa in/ali angioedem1
It was primarily designed as a pharmacokinetic study (see section 5.2). 
Zasnovana je bila predvsem kot farmakokinetična študija (glejte poglavje 5.2).
Some patients taking STAYVEER were found to have abnormal liver function tests. 
Nekateri bolniki, ki so jemali zdravilo STAYVEER, so imeli nenormalne rezultate preiskav delovanja jeter.
Hypersensitivity reactions (including dermatitis, pruritus and rash)2 
Bolezni imunskega sistema pogosti preobčutljivostne reakcije (vključno z dermatitisom, pruritusom in izpuščajem)2
In animal models of pulmonary hypertension, chronic oral administration of bosentan reduced pulmonary vascular resistance and reversed pulmonary vascular and right ventricular hypertrophy. 
Na živalskih modelih pljučne hipertenzije se je po dolgotrajnem peroralnem dajanju bosentana zmanjšal pljučni žilni upor in izboljšala pljučna žilna hipertrofija in hipertrofija desnega prekata.
STAYVEER tablets contain bosentan, which blocks a naturally occurring hormone called endothelin-1 (ET-1), which causes blood vessels to narrow. 
Tablete zdravila STAYVEER vsebujejo bosentan, ki zavre naravni hormon, imenovan endotelin-1
Contents of the pack and other information 
Shranjevanje zdravila STAYVEER Vsebina pakiranja in dodatne informacije
However, no effects on general development, growth, sensory, cognitive function and reproductive performance were detected at 7 (males) and 19 (females) times the human therapeutic exposure at Day 21 post partum. 
Kljub temu pa na 21. dan po skotitvi niso opazili nobenih učinkov na splošni razvoj, rast, senzorne in kognitivne funkcije ter na reproduktivno sposobnost pri 7-kratniku (samci) in 19-kratniku (samice)
The mean pulmonary vascular resistance was significantly reduced in the bosentan group (with a predominant effect observed in the subgroup of patients with bidirectional intracardiac shunt). 
V skupini, ki je prejemala bosentan, je bil povprečni upor pljučnih žil pomembno manjši (pri čemer so največji učinek opazili pri podskupini bolnikov z dvosmernim intrakardialnim šantom).
In this open-label randomised study with the bosentan 32 mg dispersible tablet formulation, 64 children with stable PAH from 3 months to 11 years of age were randomised to 24 weeks' bosentan treatment 2 mg/kg twice daily (n = 33) or 2 mg/kg three times daily (n = 31). 
V tej odprti, randomizirani študiji z bosentanom v obliki 32 mg disperzibilnih tablet je bilo 64 otrok s stabilno PAH, starih od 3 mesecev do 11 let, randomiziranih v 24-tedensko zdravljenje z bosentanom 2 mg/kg dvakrat dnevno (n = 33) ali 2 mg/kg trikrat dnevno (n = 31).
Adverse reactions were defined as events occurring in at least 1% of patients on bosentan and at a frequency at least 0.5% more than on placebo. 
Neželeni učinki so bili opredeljeni kot dogodki, ki so se pojavili pri vsaj 1 % bolnikov na bosentanu in z vsaj 0,5 %
The treatment in adults is usually started for the first 4 weeks with 62.5 mg twice daily (morning and evening), from then your doctor will usually advise you to take a 125 mg tablet twice daily, depending on how you react to STAYVEER. 
Zdravljenje pri odraslih se običajno začne za 4 tedne z odmerkom 62,5 mg dvakrat na dan (zjutraj in zvečer), nakar vam bo vaš zdravnik glede na to, kakšen je vaš odziv na zdravilo STAYVEER, verjetno svetoval, da začnete z jemanjem 125 mg tablet dvakrat na dan.
Bosentan is an inducer of CYP2C9 and CYP3A4 and possibly also of CYP2C19 and the P-glycoprotein. 
Bosentan je induktor izoencimov CYP2C9 in CYP3A4 ter morebiti tudi CYP2C19 in P-glikoproteina.
The most common adverse reaction was headache of mild to moderate intensity. 
Najpogostejši neželeni učinek je bil blag do srednje močan glavobol.
• simvastatin (used to treat hypercholesterolaemia). 
• simvastatin (uporablja se za zdravljenje zvišane koncentracije holesterola v krvi).
Paediatric pharmacokinetic data have shown that bosentan plasma concentrations in children with PAH aged from 1 year to 15 years were on average lower than in adult patients and were not increased by increasing the dose of STAYVEER above 2 mg/kg body weight or by increasing the dosing frequency from twice daily to three times daily (see section 5.2). 
Pediatrična populacija Podatki pediatrične farmakokinetike so pokazali, da so bile povprečne koncentracije bosentana v plazmi pri otrocih s PAH, starih od 1 do 15 let, nižje kot pri odraslih bolnikih in da se z zvišanjem odmerka zdravila STAYVEER nad 2 mg/kg telesne mase ali s povečanjem pogostnosti odmerjanja z dvakrat dnevno na trikrat dnevno niso zvečale (glejte poglavje 5.2).
Ketoconazole: Co-administration for 6 days of bosentan 62.5 mg twice daily with ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan approximately 2-fold. 
Ketokonazol: Pri 6-dnevni sočasni uporabi bosentana v odmerku 62,5 mg dvakrat na dan in ketokonazola, močnega zaviralca CYP3A4, se je plazemska koncentracija bosentana zvišala približno za dvakrat.
Based on physicochemical properties and the high degree of protein binding, bosentan is not expected to be removed from the circulation by dialysis to any significant extent (see section 4.2). 
Kliničnih izkušenj pri dializno odvisnih bolnikih ni. Na podlagi fizikalno-kemičnih lastnosti in visoke stopnje vezave na beljakovine ne pričakujemo, da bi lahko z dializo iz krvnega obtoka odstranili veliko bosentana (glejte poglavje 4.2).
Tadalafil: Bosentan (125 mg twice daily) reduced tadalafil (40 mg once per day) systemic exposure by 42% and Cmax by 27% following multiple dose co-administration. 
Tadalafil: Bosentan (125 mg dvakrat na dan) je po sočasnem dajanju večkratnega odmerka zmanjšal sistemsko izpostavljenost tadalafilu (40 mg enkrat na dan) za 42 % in Cmax za 27 %.
The mean duration of exposure to bosentan was 1.9 years ± 0.7 years (min: 0.1 years; max: 3.3 years) and patients were observed for a mean of 2.0 ± 0.6 years. 
Povprečno trajanje izpostavljenosti bosentanu je bilo 1,9 let ± 0,7 let; (najmanj 0,1 let, največ 3,3 leta), bolnike pa so opazovali povprečno 2,0 ± 0,6 let.
FUTURE 1 was an open-label, uncontrolled study that was conducted with the dispersible tablet formulation of bosentan administered at a maintenance dose of 4 mg/kg twice daily to 36 patients from 2 to 11 years of age. 
FUTURE 1 je bila odprta, nenadzorovana študija, ki so jo izvajali z bosentanom v obliki disperzibilnih tablet v vzdrževalnem odmerku 4 mg/kg dvakrat dnevno, ki so ga dajali 36 bolnikom,
The film-coat contains hypromellose, glycerol triacetate, talc, titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172) and ethylcellulose. 
Filmska obloga vsebuje hipromelozo, gliceriltriacetat, smukec, titanov dioksid (E171), rumen železov oksid
PVC/PE/PVDC/aluminium-blisters containing 14 film-coated tablets. 
PVC/PE/PVDC/aluminij pretisni omot s 14 filmsko obloženimi tabletami.
56 film-coated tablets 112 film-coated tablets 
56 filmsko obloženih tablet 112 filmsko obloženih tablet
Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 122 (study AC-052-401 [RAPIDS-1]) and 190 (study AC-052-331 [RAPIDS-2]) adult patients with systemic sclerosis and digital ulcer disease (either ongoing digital ulcers or a history of digital ulcers within the previous year). 
122 (študija AC-052-401 [RAPIDS-1]) in 190 (študija AC-052-331 [RAPIDS-2]) odraslih bolnikih s sistemsko sklerozo in boleznijo razjed prstov (bodisi nastajajočimi razjedami prstov ali z anamnezo razjed prstov v prejšnjem letu).
There are no data on the safety and efficacy in patients under the age of 18 years. 
Pediatrična populacija Podatkov o varnosti in učinkovitosti pri bolnikih pod 18 let ni. Farmakokinetični podatki za zdravilo
Gastrooesophageal reflux disease Diarrhoea 
Bolezni prebavil pogosti gastroezofagealna refluksna bolezen driska
In rats, oral administration of bosentan for 2 years produced a small, significant increase in the combined incidence of thyroid follicular cell adenomas and carcinomas in males, but not in females, at plasma concentrations about 9 to 14 times the plasma concentrations achieved at the therapeutic dose in humans. 
Pri podganah je peroralno dajanje bosentana preko obdobja dveh let povzročilo majhno, a pomembno povečanje incidence adenomov in karcinomov ščitničnih folikularnih celic pri samcih, ne pa pri samicah, pri plazemskih koncentracijah, približno 9- do 14-krat višjih od plazemskih koncentracij,
Treatment with bosentan has been associated with dose-dependent elevations in liver aminotransferases and decreases in haemoglobin concentration (see section 4.4). 
Zdravljenje z bosentanom so povezovali z zvišanjem vrednosti jetrnih aminotransferaz, odvisnim od odmerka, in znižanjem koncentracije hemoglobina (glejte poglavje 4.4).
Plasma concentrations of bosentan metabolites increased about 2-fold in these patients as compared with subjects with normal renal function. 
Pri teh bolnikih so se plazemske koncentracije presnovkov bosentana povišale za približno 2-krat v primerjavi z osebami z normalnim ledvičnim delovanjem.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON WITH 56 AND 112 TABLETS 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA S 56 IN 112 TABLETAMI
The median exposure to study treatment was 4.5 (range: 0.5-10.0) days in the bosentan group and 4.0 (range: 2.5-6.5) days in the placebo group. 
Mediana izpostavljenost študijskemu zdravljenju je bila v skupini z bosentanom 4,5 (razpon 0,5-10,0) dni, v skupini s placebom pa 4,0 (razpon 2,5-6,5) dni.
Of the 22 patients stable at week 8, 6 improved at week 12/16 and 4 deteriorated compared with baseline. 
Od 22 v 8. tednu stabilnih bolnikov se je pri 6 bolnikih stanje izboljšalo v 12./16.
The pharmacokinetics of bosentan have mainly been documented in healthy subjects. 
5.2 Farmakokinetične lastnosti Farmakokinetiko bosentana so preučevali zlasti pri zdravih osebah.